Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare

Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare  Medscape Precision cancer therapy effective in both children and adults  Medical Xpress Kinase inhibitor larotrectinib shows durable anti-tumor abilities in patients of all ages with 17 un  EurekAlert (press release)Full coverage

Read More ...
Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare published February 22, 2018 at 06:37PM. Original Source Link : https://www.medscape.com/viewarticle/892971

loading...